Compare ANNX & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | LGIH |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 1.1B |
| IPO Year | 2020 | 2013 |
| Metric | ANNX | LGIH |
|---|---|---|
| Price | $5.32 | $46.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | $16.50 | ★ $75.90 |
| AVG Volume (30 Days) | ★ 1.9M | 409.4K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $1,705,504,000.00 |
| Revenue This Year | N/A | $2.32 |
| Revenue Next Year | $16,320.74 | $17.94 |
| P/E Ratio | ★ N/A | $515.78 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.85 | $33.55 |
| 52 Week High | $7.18 | $69.42 |
| Indicator | ANNX | LGIH |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 55.32 |
| Support Level | $5.28 | $45.69 |
| Resistance Level | $5.61 | $49.51 |
| Average True Range (ATR) | 0.30 | 2.26 |
| MACD | -0.03 | -0.14 |
| Stochastic Oscillator | 40.34 | 75.68 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.